Supply of chlorthalidone 25 (HYGROTON) 25 mg tablet bottle by Link Medical Products Ltd Warriewood

Overview

The Therapeutic Goods Act 1989 (TGA) was enacted to regulate the supply of therapeutic goods in Australia, ensuring that such goods are of acceptable quality, efficacy, and safety. This legislation was introduced to address the need for a comprehensive regulatory framework governing the therapeutic goods industry, encompassing medicines, medical devices, and other related products. The Act is administered by the Therapeutic Goods Administration, a department within the Commonwealth of Australia's Department of Health, with the primary policy objective being the protection of public health by regulating therapeutic goods. In specific cases, such as the one described in the 2013 Gazette, the Act allows for the supply of non-compliant products under certain conditions, provided that they meet specified criteria to ensure the safety and efficacy of the goods supplied. This particular case involved the supply of chlorthalidone tablets by Link Medical Products Ltd, which did not conform to the dissolution requirements of the United States Pharmacopeia monograph due to the paddle speed used in testing.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation of therapeutic goods in Australia, encompassing a wide range of products such as medicines, medical devices, and blood and blood components. The Act governs entities and individuals involved in the supply, manufacture, or advertisement of therapeutic goods, ensuring that these goods meet quality, safety, and efficacy standards. The Act's jurisdictional reach extends across the Commonwealth, making it a national legislation that applies uniformly across Australia. The Act's application is broad, covering both domestic and imported goods, and it includes provisions for the regulation of clinical trials and advertising of therapeutic goods. Certain goods, such as blood products supplied for personal use, may be exempt from the Act’s requirements. The scope of the Act can be further refined through subordinate instruments, which may specify particular conditions or additional requirements for certain therapeutic goods or activities. The Act also provides mechanisms for the Therapeutic Goods Administration to grant consents or approvals under specific conditions, as demonstrated in the case of the supply of chlorthalidone 25 mg tablets, where the dissolution test method and product specifications were modified to meet regulatory standards.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) is a pivotal piece of Australian legislation governing the supply and regulation of therapeutic goods. Under section 14(1), the delegate of the Secretary of the Department of Health has the authority to consent to the supply of specific therapeutic goods that do not fully conform to certain standards. In this instance, section 14(1) was exercised to allow the supply of chlorthalidone 25 (HYGROTON) 25 mg tablets, which have a dissolution test method that deviates from the United States Pharmacopeia (USP) monograph requirements (subsection 14(1)(a)). The consent given by the delegate under section 15(1) of the Act is conditional. Firstly, the dissolution test method specified in the Company letter will employ a paddle speed of 100 rpm instead of the USP monograph’s specified 75 rpm. Secondly, the finished product must meet or exceed all other requirements of the USP monograph as modified by the Company’s letter dated September 10, 2013. Thirdly, no other changes are permitted to the product except those separately approved under section 9D(3) of the Act as outlined in the Company letter dated October 29, 2013. Under the Act, entities such as Link Medical Products Ltd must adhere to the stringent requirements and conditions set by the Department of Health for the supply of therapeutic goods. This includes ensuring that any deviations from standard requirements, such as the dissolution test method, are clearly documented and approved. Furthermore, the entity must maintain compliance with all other relevant specifications as stipulated in the USP monograph and any modifications agreed upon. Breach of the conditions set forth under section 15(1) of the Act could result in severe consequences. The Therapeutic Goods Act provides for both civil and criminal penalties for non-compliance. Civil penalties may include fines up to a specified maximum amount, as determined by the relevant court, and criminal penalties can include imprisonment, particularly if the breach results in harm to consumers. The exact penalties depend on the nature and severity of the breach, as outlined in the Act.